Loading patent…
AssigneesMogam Biotechnology Institute, Pusan National University Industry-University Cooperation Foundation
InventorsBok Luel Lee, Kurokawa Kenji, Dong-Jun Jung, Jang-Hyun An, Yu-Jin Jeon, Na Hyang Kim, Takahashi Kazue, Eunmi Kim, Dong Ho Ahn
Estimating the term…
The present invention relates to a vaccine composition for preventing staphylococcus aureus infection containing, as an active ingredient, a ribitol-phosphate which has been modified only by a β-configuration in N-Acetylglucosamine (GlcNAc), a repeating unit of the ribitol-phosphate, or a wall teichoic acid (WTA) containing the repeating unit. The composition according to the present invention contains a coupling motif (an epitope) for an anti-WTA antibody, and thus can be effectively used as a vaccine composition or to prevent staphylococcus aureus infection by generating anti-WTA antibody.
A vaccine composition for preventing staphylococcus aureus infection comprising a native form of WTA containing a ribitol-phosphate which has been modified by N-acetylglucosamine (GlcNAc), which comprises, as an active ingredient:
A method for preparing anti-WTA antibodies of S. aureus, which comprises the steps of:
A method for preventing staphylococcus aureus infection, which comprises administering to a mammal the separated and purified ribitol-phosphate, the repeating unit of the ribitol-phosphate or the WTA containing the repeating unit obtained in Step (2) or the anti-WTA antibodies obtained in Step (3).
A method for preparing a vaccine composition for preventing staphylococcus aureus infection using the separated and purified ribitol-phosphate, the repeating unit of the ribitol-phosphate or the WTA containing the repeating unit of the ribitol-phosphate obtained in Step (2) or the anti-WTA antibodies obtained in Step (3).
Dependencies are inferred from the claim text.